Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
CONV01-α is targeting the post-Lu-PSMA prostate cancer gap. Convergent now faces the Phase 3 test that will decide its real value.
Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
T-CURX and Pantherna are combining CAR-T, mRNA and LNP platforms. Europe’s in vivo cell therapy race just became more serious.
Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
Amgen’s Imdylltra has European approval in relapsed small cell lung cancer. Survival data now face reimbursement and adoption tests.
Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
Fulgent Genetics has a diagnostics base and a cancer drug signal. FID-007 now faces the tougher Phase 3 test.
Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
Minghui and Qilu’s MHB088C data show durable disease control in mCRPC. Find out why the B7-H3 ADC still faces key clinical tests.
Oricell’s ASCO 2026 liver cancer data put GPC3 CAR-T back in the spotlight
Find out how Oricell’s Ori-C101 CAR-T data could reshape expectations for late-line liver cancer treatment after ASCO 2026.
Can Lilly turn Hanmi’s sonefpeglutide into the next long-acting GLP-2 rare disease bet?
Read why Lilly’s Hanmi sonefpeglutide deal could reshape long-acting GLP-2 therapy for short bowel syndrome.
Can enicepatide and petrelintide help Genentech build a differentiated obesity franchise?
Genentech advances enicepatide and petrelintide obesity data at ADA 2026. Find out why Roche’s strategy matters now.
Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
Ivonescimab showed an overall survival benefit in HARMONi-6. Read how the data could reshape first-line squamous NSCLC treatment.
Is Pfizer’s Braftovi regimen becoming the new benchmark for BRAF-mutant colorectal cancer?
Pfizer’s Braftovi data strengthen its role in BRAF V600E metastatic colorectal cancer. Find out what this could change next.